Triamterene 50mg / Chlortalidone 50mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Triamterene + Chlortalidone on the MHRA register
Triamterene 50mg / Chlortalidone 50mg tablets
Triamterene 50mg / Chlortalidone 50mg tablets
Triamterene 50mg / Chlortalidone 50mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 16 studies.
Reviews & meta-analyses: 1 · 2020–2025
Showing all 16 studies, sorted by most relevant.
Tiara Fitrizal, S. Misfadhila, H. Rivai
International Journal of Pharmaceutical Sciences and Medicine, 2021
G. Sodeifian, Chandrasekhar Garlapati, S. M. Hazaveie, et al.
Journal of Chemical & Engineering Data, 2020
Heidi R. Abd El-Hadi, M. Eissa, H. Zaazaa, et al.
BMC Chemistry, 2023
Abstract Triamterene (TRI) and xipamide (XIP) mixture is used as a binary medication of antihypertension which is considered as a major cause of premature death worldwide. The purpose of this research is the quantitative and qualitative analysis of this binary mixture by green univariate and multivariate spectrophotometric methods. Univariate methods were zero order absorption spectra method (D 0 ) and Fourier self-deconvolution (FSD), as TRI was directly determined by D 0 at 367.0 nm in the range (2.00–10.00 µg/mL), where XIP show no interference. While XIP was determined by FSD at 261.0 nm in the range (2.00–8.00 µg/mL), where TRI show zero crossing. Multivariate methods were Partial Least Squares, Principal Component Regression, Artificial Neural Networks, and Multivariate Curve Resolution-Alternating Least Squares. A training set of 25 mixtures with different quantities of the tested components was used to construct and evaluate them, 3 latent variables were displayed using an experimental design. A set of 18 synthetic mixtures with concentrations ranging from (3.00–7.00 µg/mL) for TRI and (2.00–6.00 µg/mL) for XIP, were used to construct the calibration models. A collection of seven synthetic mixtures with various quantities was applied to build the validation models. All the proposed approaches quantitative analyses were evaluated using recoveries as a percentage, root mean square error of prediction, and standard error of prediction. Strong multivariate statistical tools were presented by these models, and they were used to analyze the combined dosage form available on the Egyptian market. The proposed techniques were evaluated in accordance with ICH recommendations, where they are capable of overcoming challenges including spectral overlaps and collinearity. When the suggested approaches and the published one were statistically compared, there was no discernible difference between them. The green analytical method index and eco-scale tools were applied for assessment of the established models greenness. The suggested techniques can be used in product testing laboratories for standard pharmaceutical analysis of the substances being studied.
Abstract licence: CC BY
K. To, K. Cheung, W. Cho
Journal of Cancer Research and Clinical Oncology, 2023
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Mina Delkhani, M. Khajenoori, A. H. Asl
Arabian Journal for Science and Engineering, 2024
D. A. Devi, P. G. Bhavani
Future Journal of Pharmaceutical Sciences, 2023
Abstract Background According to the information gathered from the literature, no technique for UPLC of triamterene and hydrochlorothiazide employing QbD in the formulations has been published. The technique development by incorporating QbD and validating for accuracy, linearity, precision, LOQ, LOD, ruggedness and selectivity as per ICH is part of the work’s modernity. Results Screening investigations led to the selection of cmps. Peak tailing was evaluated as a metric of technique robustness based on these important analytical attributes, namely retention time. With a 0.1 percent OPN: methanol (40:60) mobile phase, a flow rate of 0.3 ml/min, a wave length of 224 nm, an injection volume of 41, and a run time of 6 min, the best chromatographic separation was attained. Conclusions The method was verified using ICH criteria, which ensure a high level of linearity, accuracy, precision, specificity and robustness. As a result, the suggested approach is regarded as a quick and accurate method for estimating triamterene and hydrochlorothiazide at the same time.
Abstract licence: CC BY
D. Thieme, Kai Weigel, P. Anielski, et al.
Drug testing and analysis, 2024
- Chlorthalidone
- Doping in Sports
- Hair
Chlortalidone (CLT) is a thiazide-type diuretic with high affinity for the erythrocyte carbonic anhydrase. Therapeutically, it is mostly used to treat edema and hypertension due to liver cirrhosis, heart insufficiency, or renal dysfunction. Although diuretics and masking agents are prohibited by the World Anti-Doping Agency (WADA) at all times in sports, substances belonging to this category are constantly detected in athlete samples, according to WADA's annual testing figures. Within this group of structurally diverse compounds, a threshold of 20 ng/mL has been introduced for six substances solely due to their presence as contaminants in other permitted drugs because of pharmaceutical production processes. In a recent presumptive doping case with a low urinary CLT concentration, the question of unintentional doping, for example, by contaminated non-steroidal anti-inflammatory drug intake, arose. To examine this potential scenario, a co-elimination of low-dose CLT and hydrochlorothiazide (HCTA; 20 × 50 μg, 0.2 mg/day each) was conducted on five consecutive days in two volunteers. Urine samples were subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS). Moreover, we examined the incorporation of CLT in scalp hair. HCTA is rapidly excreted renally in comparatively high concentrations. In contrast, the elimination of CLT is considerably slower (terminal elimination half-life extended by a factor of 12) and, consequently, much less concentrated in corresponding urine samples (45 and 53 ng/mL, respectively). Conversely, a higher hair incorporation of chlorthalidone was observed with simultaneous dosing of both. The results suggest that an unintentional intake of sub-therapeutic CLT doses due to contamination might result in an adverse analytical finding.
Abstract licence: CC BY-NC-ND
Hend A Awad, Mohamed I Fetouh, Amal A. Sultan, et al.
Drug Development and Industrial Pharmacy, 2024
- Hydrochlorothiazide
- Triamterene
- Antihypertensive Agents
P. Kintz
Clinica chimica acta; international journal of clinical chemistry, 2024
- Hair
- Substance Abuse Detection
- Chlorthalidone
Jing Yao, Xuejia Zhao, Jingjing Wang, et al.
Current Pharmaceutical Analysis, 2024
Background: Triamterene is a potassium-conserving diuretic mainly used in the treatment of edematous diseases. Although there are some methods to measure the content of triamterene, the existing methods have the characteristics of sample destructiveness and low flux, making it difficult to meet the needs of online monitoring. In recent years, transmission Raman spectroscopy (TRS), as a new technology for the determination of drug content, has emerged as being nondestructive and rapid and provides a new method for the determination of triamterene content. Objective: In this study, we used transmission Raman spectroscopy combined with partial least squares (PLS) approaches to establish a six concentration levels model for measuring the content of triamterene. The model was applied to determine whether tablets are commercially available. Methods: Firstly, TRS was used to collect the spectra of the principal components and mixed excipients of triamterene, and the feasibility test was carried out. Secondly, six concentration levels were determined by the design of experimental (DOE), and hand-made tablets were prepared to obtain corresponding spectra. The content prediction model was established by the PLS method, and the content of triamterene was determined by high-performance liquid chromatography (HPLC) to correct the model. Finally, the model was applied to the determination of triamterene in commercially available tablets. Results: The results showed that the established model was successfully applied to the determination of triamterene. The values of RMSEC (0.0089783) and RMSECV (0.0097241) of the final model were very low and close to each other. The relative error of 12 hand-made tablets predicted by this model was less than 5% compared with the results determined by HPLC. In addition, in the process of applying the model to the determination of the content of commercially available tablets, the accuracy of the model can be significantly improved by adding the spectrum of commercially available tablets. The corrected model was used to determine the content of triamterene in two commercially available tablets. The results showed that the relative error was less than 5%. Conclusion: We described a new strategy to analyze the content of active pharmaceutical ingredients (API) in triamterene tablets by TRS with PLS. The established model has the advantage of non-destructive and rapid quantitation, which can provide a new method for real-time monitoring of production lines and promote the development of process analytical technology (PAT).
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.